- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00121134
Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer
Anti-Angiogenesis Treatment After Preoperative Chemotherapy: A Pilot Study in Women With Operable Breast Cancer
The purpose of this research study is to study the effects (good and bad) of bevacizumab alone, bevacizumab with low-dose continuous chemotherapy (called metronomic chemotherapy), or bevacizumab with capecitabine, on you and your cancer. The goals of the study will be to:
- Examine the safety of these drugs
- See how easy or difficult it is to be treated with them
- Monitor for any signs of recurrent cancer
- Look at blood markers that might indicate how the treatment is working
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study is broken into 4 groups (A, B, C, and D). Enrollment closed to all groups in May 2008.
The first forty subjects (Group A) in this study were treated with Bevacizumab only, which is given through a vein over 1-2 hours every 3 weeks, for a total of approximately 12 months (17 cycles). Each cycle consists of 3 weeks.
The next forty subjects (Group B) were treated with Bevacizumab and metronomic CM chemotherapy. These subjects took cyclophosphamide (1 pill by mouth every day), methotrexate, (1 pill taken by mouth twice a day for the first two days of each week) and Bevacizumab (once every 3 weeks). The treatments with cyclophosphamide, methotrexate and Bevacizumab will continue for approximately 6 months (8 cycles). Then for the next 6 months, they received Bevacizumab treatments only. The total time on this study will be about 12 months (17 cycles).
The next forty subjects (Group C) were treated with Bevacizumab and Capecitabine chemotherapy. These subjects took Capecitabine pills twice a day for 14 days, then one week of rest, to complete a 21-day cycle. There will be a total of 6 cycles of Capecitabine, meaning 18 weeks of treatment with both Capecitabine and Bevacizumab. Then received Bevacizumab treatments only (11 cycles) to complete 12 months of therapy. Total duration of your treatment will be about 12 months or 17 cycles of therapy.
The last forty subjects (Group D) are being treated with Bevacizumab and Capecitabine chemotherapy on a different schedule. These subjects will take Capecitabine pills twice a day for 7 days, then one week of rest and repeat this for a total of 24 weeks (6 cycles). Each cycle will last for 4 weeks (28 days). There will be a total of 6 cycles of Capecitabine, meaning 24 weeks of treatment with both Capecitabine and Bevacizumab. Bevacizumab will be given every two weeks for a total of 24 weeks (6 cycles). Then they will receive Bevacizumab treatments only, every 3 weeks for additional 27 weeks (9 cycles) to complete 12 months of therapy. For the last 9 cycles of Bevacizumab therapy each cycle will consist of 3 weeks. Total duration of treatment will be about 12 months or 15 cycles of therapy.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
California
-
San Francisco, California, États-Unis, 94122
- University of California, San Francisco
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Indiana University Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, États-Unis, 02115
- Beth Israel Deaconess Medical Center
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27701
- University of North Carolina
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging
- Patients must have completed preoperative (neoadjuvant) chemotherapy with a standard chemotherapy regimen. No more chemotherapy should be planned.
- Patients must have completed definitive resection of primary tumor with adequate excision of gross disease.
- For patients receiving adjuvant radiation therapy, treatment must be completed prior to initiation of protocol therapy.
- Patients must have the presence of significant residual invasive disease on pathologic review following their preoperative chemotherapy.
- LVEF > institutional limits of normal after preoperative chemotherapy, as assessed by ECHO or nuclear medicine gated study, within 30 days prior to initiating protocol-based treatment.
- ECOG performance status 0-1
Exclusion Criteria:
- Inadequate organ function, as measured by laboratory assessment after preoperative chemotherapy and within 14 days of beginning protocol-based treatment
- Patients with metastatic disease are ineligible.
- Known HIV infection
- Patients may not be pregnant, expect to become pregnant, plan to conceive a child while on study, or breastfeeding
- Uncontrolled intercurrent illness
- Non-healing wounds or major surgical procedures (such as breast surgery) other than that for venous access device or diagnostic study are not permitted within 28 day prior to enrollment
- History of abdominal fistula, GI perforation, intra-abdominal abscess, or serious, non-healing wound, ulcer, or bone fracture within 6 months prior to initiating bevacizumab
- Patients with any history of arterial thromboembolic events, including transient ischemic attack (TIA), cerebrovascular event (CVA), unstable angina, or myocardial infarction (MI) within the past 6 months. Patients with clinically significant peripheral arterial disease should also be excluded
- History of bleeding diathesis or coagulopathy
- History of grade 3 or 4 allergic reactions to compounds of similar chemical or biologic composition to cyclophosphamide (such as other alkylating agents) or methotrexate (such as other antimetabolites)
- Prior history of malignancy treated without curative intent, excluding nonmelanomatous skin cancer
- Patients with large or rapidly accumulating pleural or abdominal effusions
- Current use of anticoagulants is allowed as long as patients have been on a stable dose for more than two weeks with stable INR
- Chronic therapy with full dose aspirin (< 325 mg/day) or standard non-steroidal anti-inflammatory agents is allowed
- Patients may not receive other investigational agents while on study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Group A
Bevacizumab Alone
|
Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
Autres noms:
|
Expérimental: Group B
Bevacizumab with cyclophosphamide and methotrexate
|
Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
Autres noms:
Once a day for 6 months
Autres noms:
Twice daily for the first two days of every week for 6 months
Autres noms:
|
Expérimental: Group C
capecitabine, 14 days on/7 days off scheduling, and bevacizumab
|
Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
Autres noms:
Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks) Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)
Autres noms:
|
Expérimental: Group D
capecitabine 7 days on/7 days off scheduling, and bevacizumab
|
Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
Autres noms:
Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks) Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
The Completion Rate of 1 Year of Bevacizumab Therapy for All Four Cohorts
Délai: 1 year
|
1 year
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Harold J Burstein, MD, PhD, Dana-Farber Cancer Institute
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies de la peau
- Tumeurs
- Tumeurs par site
- Maladies du sein
- Tumeurs mammaires
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs de la synthèse des acides nucléiques
- Inhibiteurs d'enzymes
- Agents antirhumatismaux
- Antimétabolites, Antinéoplasique
- Antimétabolites
- Agents antinéoplasiques
- Agents immunosuppresseurs
- Facteurs immunologiques
- Agents antinéoplasiques, alkylants
- Agents d'alkylation
- Agonistes myéloablatifs
- Agents antinéoplasiques immunologiques
- Inhibiteurs de l'angiogenèse
- Agents modulateurs de l'angiogenèse
- Substances de croissance
- Inhibiteurs de croissance
- Agents dermatologiques
- Agents de contrôle de la reproduction
- Agents abortifs, non stéroïdiens
- Agents abortifs
- Antagonistes de l'acide folique
- Cyclophosphamide
- Capécitabine
- Bévacizumab
- Méthotrexate
Autres numéros d'identification d'étude
- 05-055
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer du sein
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie
Essais cliniques sur Bevacizumab
-
Dana-Farber Cancer InstituteBristol-Myers Squibb; Genentech, Inc.Complété
-
Koen RoversHoffmann-La Roche; Comprehensive Cancer Centre The Netherlands; Dutch Cancer...RecrutementCancer colorectal | Tumeurs péritonéales | Tumeur colorectale | Carcinose péritonéale | Carcinome colorectal | Cancer péritonéal | Métastases péritonéales | Adénocarcinome colorectal | Tumeurs colorectales malignes | Tumeur péritonéale Carcinomatose secondaire maligne | Tumeur péritonéale maligne secondairePays-Bas, Belgique
-
National Cancer Institute (NCI)Actif, ne recrute pasCarcinome récurrent des trompes de Fallope | Carcinome ovarien récurrent | Carcinome péritonéal primitif récurrent | Cystadénocarcinome à cellules claires de l'ovaire | Adénocarcinome endométrioïde ovarien | Cystadénocarcinome séreux ovarien | Adénocarcinome à cellules claires de l'endomètre | Adénocarcinome... et d'autres conditionsÉtats-Unis
-
Harbin Medical UniversitySun Yat-sen University; Fudan University; Cancer Institute and Hospital, Chinese... et autres collaborateursInconnueTumeurs colorectales | ChimiothérapieChine
-
Hoffmann-La RocheComplétéGlioblastome multiformeSuisse, France, Royaume-Uni, Danemark
-
Spanish Cooperative Group for the Treatment of...Roche Pharma AGComplété
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.ComplétéCancer du col de l'utérus | Glioblastome | Cancer des ovaires | Cancer du poumon | Cancer rectalChine
-
Azienda Ospedaliero, Universitaria PisanaComplété
-
National Taiwan University HospitalRésilié
-
National Cancer Institute (NCI)Actif, ne recrute pasMélanome cutané de stade IV AJCC v6 et v7 | Mélanome cutané de stade IIIC AJCC v7 | Mélanome non résécableÉtats-Unis